Videregen Limited
Videregen is dedicated to advancing tissue repair through innovative stem cell science, focusing on thymus regeneration and trachea organ regeneration. Their proprietary BioThymus technology aims to rejuvenate thymus function to treat immune deficiencies, autoimmunity, organ transplant tolerance, and age-related immune deterioration. They are also developing tissue-engineered tracheal transplants to treat severe airway diseases. The company's mission is to translate scientific advances into regenerative therapies that restore immune and tissue function, improving patient outcomes and addressing significant medical needs.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Bioengineered thymus implant (preclinical platform)
A tissue-engineered thymus construct combining expanded thymic epithelial cells, interstitial cells and a 3D scaffold intended to restore thymic function and T cell education; currently at preclinical development.
Decellularised tracheal scaffold reseeded with autologous cells
A clinical-stage tracheal replacement product consisting of decellularised human tracheal scaffold reseeded with the patient's autologous mesenchymal stromal cells and airway epithelial cells, manufactured under GMP conditions.
Bioengineered thymus implant (preclinical platform)
A tissue-engineered thymus construct combining expanded thymic epithelial cells, interstitial cells and a 3D scaffold intended to restore thymic function and T cell education; currently at preclinical development.
Decellularised tracheal scaffold reseeded with autologous cells
A clinical-stage tracheal replacement product consisting of decellularised human tracheal scaffold reseeded with the patient's autologous mesenchymal stromal cells and airway epithelial cells, manufactured under GMP conditions.
Services
Design and execution of preclinical implantation studies in humanised models to assess immune reconstitution, gene expression and functional outcomes.
Process optimisation and GMP manufacturing capability for decellularised scaffolds reseeded with autologous cells, including aseptic workflows and product release considerations.
Processing of donated organs to remove cellular material and produce acellular scaffolds suitable for reseeding with patient-derived cells.
Support for preparing safety/toxicology testing and documentation to advance cell‑based products toward clinical trials, and management of ethics/regulatory approvals.
Design and execution of preclinical implantation studies in humanised models to assess immune reconstitution, gene expression and functional outcomes.
Process optimisation and GMP manufacturing capability for decellularised scaffolds reseeded with autologous cells, including aseptic workflows and product release considerations.
Processing of donated organs to remove cellular material and produce acellular scaffolds suitable for reseeding with patient-derived cells.
Support for preparing safety/toxicology testing and documentation to advance cell‑based products toward clinical trials, and management of ethics/regulatory approvals.
Expertise Areas
- Tissue engineering for organ regeneration
- Thymus biology and thymic epithelial stem cells
- Cell therapy manufacturing and GMP translation
- Decellularization and recellularization of organ scaffolds
Key Technologies
- 3D organ scaffolds
- Decellularization of donor organs
- Autologous mesenchymal stromal cell culture
- Airway epithelial cell culture
News & Updates
Update on the progress of their regenerative therapies and recent scientific findings.
Details about their research and development activities in thymus regeneration.
Initial updates on their tissue restoration projects.
Update on the progress of their regenerative therapies and recent scientific findings.
Details about their research and development activities in thymus regeneration.
Initial updates on their tissue restoration projects.